Glucotrack (GCTK) reports successful completion of first human clinical study for continuous blood glucose monitoring, shares ...

Rutherford, NJ., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focused on the design, development, and ...

Glucotrack (GCTK) announced the pricing of a “best efforts” public offering of approximately 2.6M shares of common stock. The offering price of ...

(Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that ...

Glucotrack (GCTK) announced the successful completion of its first in human clinical study, marking a significant milestone in continuous ...

Glucot (Nasdaq: GCTK), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced the pricing of a “best efforts” ...

New hire set to drive clinical development and U.S. commercialization of the continuous blood glucose monitor for people with diabetesRUTHERFORD, N.J., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Glucotrack, ...

In a stark reflection of the challenges facing the tech sector, GCTK's stock has tumbled to a 52-week low, touching down at a mere $0.06, with a market capitalization shrinking to just $0.99 million.